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Highlights 
Pineoblastomas, usually found in children, are exceedingly rare in adults. Few reports have compared 
aspects of these tumors between adults and children. This study found: 
• Of the 12 patients in this series, only 5 died of their disease (average length of survival 118 
months), and 5 patients are still alive with no evidence of disease (average length of follow-up, 92 
months).  
• Patients with subtotal resections or diagnostic biopsies did not suffer a worse prognosis.  
• Progression-free survival and overall survival are much higher for adult patients than for children 
• Data suggest that pineoblastomas have a less aggressive clinical course in adults than in children. 
 
Funding and conflicts of interest:  No funding was received for this study and the authors have no 
conflicts of interest. 
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Abstract 
 
Introduction: Pineoblastomas are uncommon primitive neurectodermal tumors and most occur in 
children. They are exceedingly rare in adults. Few published reports have compared the various aspects of 
these tumors between adults and children.  
Methods: The authors report a series of 12 pineoblastomas in adults from 2 institutions over 24 years. 
The clinical, radiologic, and pathologic features, and clinical outcomes were compared with previously 
reported cases in children and adults.  
Results: Patients ranged from 24-81 years of age, and all but 1 presented with symptoms of obstructive 
hydrocephalus. Three patients underwent gross total resection, while subtotal resection was performed in 
3. Diagnostic biopsies were obtained in another 6 patients. Pathologically, the tumors had the classical 
morphological and immunohistochemical features of pineoblastomas. Postoperatively, 10 patients 
received radiotherapy and 5 received chemotherapy. Compared with previously reported cases, several 
differences were noted in clinical outcomes. Of the 12 patients, only 5 (42%) died of their disease 
(average length of survival, 118 months), another 5 (42%) patients are alive with no evidence of disease 
(average length of follow-up, 92 months). One patient died of unrelated causes and 1 was lost to follow-
up. Patients with subtotal resections or diagnostic biopsies did not suffer a worse prognosis. Of the 9 
Gener,  3 
 
 
 
patients with biopsy or subtotal resection, 4 are alive, 4 died of their disease, and 1 died of an unrelated 
hemorrhagic cerebral infarction.  
Conclusions: Although this series is small, the data suggest that pineoblastomas in adults have a less 
aggressive clinical course than in children. 
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Introduction 
Primary pineal parenchymal tumors are rare and account for 0.4% to 1% of primary central 
nervous system neoplasms in all age groups combined (7). Approximately 25-50% of primary pineal 
parenchymal tumors are pineoblastomas (20,29), WHO grade IV. These are embryonal tumors that arise 
in the region of the pineal gland, are found preferentially in children, and often disseminate extensively 
along the cerebrospinal fluid (CSF) pathways. Patients with pineoblastomas have a reported 5-year 
survival rate of only 10% (1,11). Only a few isolated case reports and small series of these tumors 
occurring in adults have been documented in the literature (4,7,17,21). In this report, we discuss the 
largest series to date of 12 cases of pineoblastomas occurring in patients older than 19 years of age who 
presented at our institutions during the last 24 years.  
 We aim to determine if there are specific pathologic, clinical, radiologic features, or surgical 
techniques that are associated with outcome.  
 
Materials and Methods 
We extracted information from the electronic medical records at Indiana University Health and 
Mayo Clinic, using the key words “pineal gland,” “pineoblastomas,” “pineal parenchymal tumor,” and 
“pineal gland tumor.” Data about the cases were transferred into a Microsoft Excel 2008 spreadsheet.  
 The following information was obtained about each patient: sex, age, race, institution, tissue 
source, specimen type, presenting symptoms and their duration, presence of hydrocephalus, tumor 
location and size, tumor invasion, spread of tumor, history of previous resection, surgical approach for 
resection, extent of resection (percentage), postoperative complications, the need for a shunt, adjuvant 
radiation, other adjuvant therapy, follow-up time, and cause of death. Patients younger than 19 years of 
age were defined as children and excluded from the study. The clinical presentation, radiological features, 
histopathological findings, treatments, and survival for all adult patients with primitive neuroectodermal 
tumors, WHO grade IV, in the pineal region were reviewed in detail.  
 A staff pathologist examined all of the pathology case materials to determine the final diagnosis. 
Tumors were examined for histologic characteristics, mitotic rate, Ki67 (MIB-1) proliferative index, 
synaptophysin, neurofilament protein and glial acidic fibrillary protein immunoreactivity, and the 
presence of rosettes. We also reviewed the available radiologic studies for each patient to determine if 
there were specific imaging characteristics in these tumors in adults that differ from those in children. 
Sum of squares for error was employed to determine the Kaplan Myers survival curves comparing the 
progression-free and overall survival of the patients using a variety of parameters.  
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Results  
Our data search spanned the last 24 years at our 2 institutions. Twelve adult patients were 
diagnosed with pinealoblastomas during 1990-2013. These patients included 2 men and 10 women (range 
24–81 years of age at diagnosis). The median age at diagnosis was 47 years. The average clinical follow-
up time was 95 months (range 0–288 months).  
 The most common clinical presentation was headaches. Additional presenting symptoms included 
blurred vision, vertigo, urinary incontinence, back pain, weight loss, gait disturbances, and lower 
extremity weakness (Table 1). Hydrocephalus was present as an initial finding in all but one of our 
patients.  
Radiographic Features 
 The reports of imaging studies were available for all 12 patients in our series. Eleven of 
the 12 patients presented with obstructive hydrocephalus. The imaging reports were available on 
all patients and 3 patients had available imaging studies that were also reviewed by our 
radiologists (Figures 1 and 2). Eleven patients demonstrated pineal masses at presentation. One 
patient presented with obstructive hydrocephalus, but no appreciable mass found on noncontrast 
computed tomography (CT) imaging. Three months after initial presentation, follow-up imaging 
on this patient demonstrated a 2-cm pineal mass.  
 The reviews of the available imaging studies in 3 patients demonstrated that the smallest 
mass was ovoid, whereas the other masses were slightly lobulated with mildly irregular margins. 
Two were well defined on postcontrast MR images, and one appeared mildly infiltrative. One 
mass was T1-isointense and T2-isointense; one was T1-isointense and T2-hyperintense; and a 
third was mildly T1-hypointense and T2-hyperintense compared with gray matter. All 3 masses 
demonstrated avid heterogeneous patterns of enhancement. Two masses demonstrated mild 
diffusion restriction diffusely. Diffusion-weighted imaging was not performed on the third case. 
One mass had no cystic components; one demonstrated a few very small internal cysts; and the 
third demonstrated a moderate size central cystic cavity. Two of the 3 patients had preoperative 
CT performed, and neither of them demonstrated the classically described “exploded” pineal 
calcifications. Rather, both demonstrated a single cluster of displaced pineal calcifications. 
 The imaging findings in our series conform to the previously described typical imaging 
characteristics, with the exceptions of the tumor that was too small to detect at presentation and 
the displaced (rather than exploded) pineal calcifications in 2 cases. Diffusion restriction was 
demonstrated in both cases that had diffusion-weighted images available. Diffusion restriction 
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has been suggested as a possible distinguishing characteristic at diagnosis (9) and a possible 
tumor marker at posttreatment follow-up (13).  
Treatment and Survival 
Initial surgical treatment data were available for all 12 of our patients. Six patients 
underwent stereotactic biopsies only. Two patients had a subtotal resection (<90% of tumor 
removed); 1 patient had a near total gross resection (>90% of tumor removed); and 3 patients 
underwent gross total resections. For patients undergoing resections, the tumors were exposed 
via suboccipital supracerebellar approach. Table 2 summarizes the surgical technique and extent 
of resection for each patient. 
 Among the 12 patients in our series, 10 received postsurgical radiation therapy. In 
addition, 5 patients completed chemotherapy. These results are shown in Table 3. 
  Follow-up information was available for 11 of our patients. The median patient follow-
up time was 95 months. Three of our patients suffered tumor recurrences. Two had local 
recurrence, and 1 had a T10 spinal metastasis with no evidence of residual pineal disease. The 
median time from diagnosis to recurrence was 144 months (12 years). All 3 patients with 
recurrences died of their disease. The median time from recurrence to death from disease was 48 
months. In addition, 2 patients died directly from their disease shortly after diagnosis because of 
increased intracranial pressure caused by tumor mass effect, whereas another died of infection 
and intraparenchymal hemorrhage not related to the tumor mass itself (unrelated stroke). The 
time from initial diagnosis to death for these 3 patients ranged for 0.5 to 11 months. The 
remaining 5 patients had an average follow-up time of 92 months and all have had no incidence 
of recurrence.  
Pathologic Features 
 Pathology reports were available for all 12 patients, and original histological sections 
were available for review in 6 (Table 4). Histologic characteristics of the tumors in all 12 
patients were consistent with the previously described morphologic and immunohistochemical 
phenotype in pinealoblastomas occurring in both children and adults.  
 All of the examined tissues showed the classically described features of a pineoblastoma. 
They are highly cellular tumors composed of monotonous overlapping hyperchromatic, round to 
oval cells with salt and pepper chromatin, and with inconspicuous to no nucleoli and scant 
eosinophilic cytoplasm. Occasional rosettes were identified (Figure 3). Notably, all of our 
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patients showed strong and diffuse immunoreactivity for synaptophysin and no immunoreactivity 
for glial acidic fibrillary protein (Figure 4). The tumors had varied mitotic rates and Ki67 
proliferative indices. The lowest reported mitosis rate was 3/10 high power field (HPF) and the 
highest was 32/10 HPF. We examined the mitotic rate and proliferative indices to determine if 
tumors with a higher proliferation or mitotic rate corresponded with a more aggressive clinical 
course.  
In our evaluation of the histologic characteristics of these tumors, we found that the 
reliable predictors of a worse clinical outcome is an increase in mitotic count (>10/10 HPF) and 
an elevated (>10%) Ki67 proliferative index. Patients with either of these two findings had a 
worse progression-free survival and overall survival. Patients were divided into 2 groups for each 
of the 2 criteria. For mitotic rate, those with greater than 10 mitoses per 10 HFP were compared 
with those with less than or equal to 10 mitoses per 10 HPF. The results of the Kaplan Myers 
survival curves are seen in Figures 5 and 6. For Ki67 proliferative index, those with a rate greater 
than 10% were compared to those with a rate of less than or equal to 10%. Those results are seen 
in Figures 7 and 8.  
Patient age at diagnosis was also examined to determine if a certain age group had worse 
overall survival. We divided our patients into age categories, 19- 29, 30-39. 40-49, 50-59, and 60 
years of age and older. The results for patient survival are shown in Table 5.  
Discussion 
There is some available literature addressing the clinical outcomes of pineoblastomas in 
adult patients. Since 1979, approximately 200 cases have been reported, some of these relevant 
series include groups of patients with heterogeneous pathologies such as different pineal region 
tumors, therefore, the exact number of adult patients with pathologically confirmed 
pineoblastoma is not completely certain. The largest study to date is from the United Kingdom 
and included 95 patients age 16 and older (30). Before that study, 2 other studies from Japan (17) 
and Germany (21) included 34 and 64 patients, respectively. A more recent study from MD 
Anderson Cancer Center (10) reported 14 adult patients. The important findings and patient 
demographics from each of these studies are presented in Table 6.  
Lutterbach and colleagues presented 101 patients, age 18 and older, from multiple 
centers, many of whom had been previously reported (2,3,5-8,12,15,16,18,19,22-26,28,29,32-
35). These cases included both pineoblastomas and pineal parenchymal tumors of intermediate 
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differentiation. Sixty-four patients harbored pineoblastomas, including both those in the review 
of all published literature from 1979 to 2002 and newly reported cases. The median survival of 
these patients was 77 months. Factors that increased survival included completeness of resection 
and extent of disease. As in our study, age and sex did not affect survival outcomes.  
Lee and colleagues presented 34 patients, age 16 and older, from the Brain Tumor 
Registry of Japan. In this study, the number of patients in the 16-18 age group is not identifiable, 
making it difficult to draw a direct comparison of their results to ours. The median survival was 
25.7 months. Upon analysis, 2 variables were noted to independently affect survival: 
completeness of resection and dose of cranial radiation. No patients with gross total resection 
died, and those receiving greater or equal to 40 Gy of radiation benefitted from a statistically 
significant survival advantage, regardless of extent of resection.  
Selvanathan et al (30) published the largest series to date in 2012 using the Surveillance, 
Epidemiology, and End Results (SEER) database from the United Kingdom. Included were 95 
patients age 16 years and older. Again, as with the study by Lee and colleagues (17), the authors 
did not divulge the number of their patients in the 16 -18 age group, making direct comparison of 
their results to ours difficult. They concluded that they only independent predictors of a better 
outcome were age at diagnosis and the presence of localized disease. Interestingly, as in our 
series, they did not see worse survival rates in patients who received subtotal resections or 
biopsies only.  
Based on our 12 cases, we reviewed our patients’ age, sex, clinical presentation, 
histologic findings, radiographic features, surgical approach, and radiation/chemotherapy 
treatment to determine if there are specific aspects of pineoblastomas in adults that are different 
from those in children. 
 In children, pineal parenchymal tumors have an equal male and female distribution. 
However, our adult patients with pinealoblastomas included 10 women and 2 men. In our review 
of the literature, 4 series showed a predominance of males (7,10,17,21) and 2 studies showed a 
slight predominance of females (11,30). Because of the rarity of these tumors, it is unlikely that 
we can predict if these tumors in adults are reliably associated with gender predominance.  
 The only histological characteristic that was statistically significant in predicting a worse 
progression-free survival was the mitotic count of >10 mitotic figures per 10 high-power fields 
(HPF). Although the difference in the Ki67 proliferate index between those with a rate of ≤10% 
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versus those with a rate >10% was not statistically significant, the data demonstrate some 
difference in these 2 groups overall and in progression-free survivals. The small sample size may 
account for the lack of statistical significance for these differences. Overall, mitotic rate and 
Ki67 proliferative indices correlate well in terms of predicting the growth potential of these 
tumors. 
 The imaging characteristics of pineoblastomas have been previously described 
(9,23,27,31). Pineoblastomas are often large (>3 cm) at presentation, and cause obstructive 
hydrocephalus in nearly all patients. Computed tomography images typically demonstrate a 
hyperattenuating mass, which reflects tumor hypercellularity. Pineal calcifications, if present, are 
often “exploded” and displaced to the periphery of the mass. MR imaging typically reveals a 
heterogeneous mass with T1 signal hypointense to isointense, and T2 signal isointense to 
hyperintense relative to gray matter, and often heterogeneous enhancement following 
administration of contrast media. Diffusion restriction may be seen, likely related to 
hypercellularity. Necrosis and hemorrhage may be present, but extensive cystic change is rare. 
Cerebrospinal fluid dissemination is common, and the entire craniospinal axis should be imaged 
when pineoblastoma is considered in the differential diagnosis.  
 Considerable overlap exists between the imaging appearance of pineoblastoma and lower 
grade primary pineal neoplasms (23,27,31). Germinomas, commonly in the differential diagnosis 
of pineal tumors, also have overlap in imaging appearance, but have been found to demonstrate 
less diffusion restriction (9).  
 All but one of our patients presented with radiographic and clinical signs of 
hydrocephalus, including headache, double vision, blurry vision, and obtundation. This is the 
most common presenting feature in all cases of pineal parenchymal tumors, among both adults 
and children. Because all but one of our patients had hydrocephalus on presentation, we did not 
evaluate hydrocephalus as an independent prognostic feature. In the other small case series 
(4,7,17,21,30), hydrocephalus was also the most common presenting feature, with the percentage 
of symptomatic patients ranging from 46–100%.  
 One of the most striking clinical differences that we observed between our patients and 
the reported pediatric patients is that progression-free survival and overall survival for adult 
patients are much higher than for children. Our patients, on average, had a 109-month 
progression-free survival among the 8 patients with clinical follow-up who did not die of their 
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initial disease. In addition, after recurrence, our patients still lived, on average, 36 months from 
the time of recurrence. In the literature, death in children with this disease is usually very rapid 
after relapse (14).  
 Also in contrast with pediatric patients, in whom gross total resection of the main tumor 
is linked to significantly better progression-free and overall survival, we observed that 3 of our 6 
patients who underwent diagnostic biopsy without formal resection were alive and free of their 
disease at their last follow-up visit. These patients received a combination of radiotherapy and 
chemotherapy after diagnosis. However, our patient with spinal metastasis eventually died of the 
disease. His initial diagnosis was also made only by biopsy, and his spinal metastasis was not 
seen until 17 years after the initial diagnosis.  
 
Conclusions 
A review of our 12 patients with this rare disease suggests that pineoblastomas in adults 
have a less aggressive clinical course than those in the pediatric population. Safe surgical 
resection and adjuvant therapy are associated with reasonable outcomes. 
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Figure Legends 
Figure 1: Pineoblastoma in a 51-year-old woman demonstrating mild diffusion restriction. 
Diffusion-weighted image demonstrates hyperintensity diffusely within the tumor relative to the 
cortex (left image). The apparent diffusion coefficient (ADC) map demonstrates isointensity 
within the tumor (middle image). The T2-weighted image demonstrates mild hyperintensity 
within the tumor (right image). 
Figure 2: Pineoblastoma with a central cystic component in a 40-year-old woman. T1-weighted 
image demonstrates isointensity relative to gray matter within the solid portions of the tumor 
(left image). Heterogeneous enhancement is demonstrated within the solid portions of the lesion 
on the post-contrast T1-weighted image (middle image). A central cystic component is 
demonstrated on the T2-weighted image (right image). 
Figure 3: Hypercellular tumor with uniform cells with high nuclear-to-cytoplasmic ratio (left upper 
image). Mitoses are abundant (right upper and left lower images). Homer-Wright rosettes are rare, but 
usually seen in pineoblastomas (right lower image). 
Figure 4: Glial acidic fibrillary protein immunostain demonstrated reactivity in the surrounding and 
infiltrated glial tissue. Immunoreactivity is absent in the tumor cells (left image). Synaptophysin is 
strongly immunoreactive in all tumor cells (right image). 
Figure 5. Progression-free survival with reference to mitotic rate (MR) (9). Patients with MR ≤ 
10/10 HPF had a median progression-free survival of 84 months. Patients with MR >10/10 HPF 
showed a median progression-free survival of 3 months.  
Stats: Log-Rank X2 = 5.0000, p = 0.025 
Figure 6. Overall survival with reference to mitotic rate (MR). Patients with MR ≤ 10% had a 
median overall survival of 108 months (average = 139.0 months). Patients with MR > 10% had a 
median overall survival of 3 months (average = 3.5 months). Log-Rank X2 = 0.8744, p = 0.350 
Figure 7. Progression-free survival with reference to Ki67 proliferative index. Patients with 
Ki67 ≤ 10% had a median progression-free survival of 144 months (average = 128.2). Patients 
with Ki67 > 10% had a median progression-free survival of 4 months (average = 30.3). Log-
Rank X2 = 1.1825, p = 0.277 
Figure 8. Overall survival with reference to Ki67 proliferative index. Patients with Ki67 ≤ 10% 
had a median overall survival of 180 months (average = 140.2 months). Patients with Ki67 > 
10% had a median overall survival of 4 months (average = 55.8 months). Log-Rank X2 = 0.7387, 
p = 0.39. 
